Onglyza, Kombiglyze XR – Heart Failure
Lawsuits allege that diabetic drugs Onglyza or Kombiglyze XR are linked to:
- congestive heart failure,
- heart attack,
- myocardial infarction and/or
- cardiovascular injury
The cases are consolidated in the Eastern District of Kentucky before the Honorable Karen Caldwell. The defendant manufacturers are Bristol-Myers Squibb and AstraZeneca. MDL 2809 was created: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR – Judicial Panel
Kombiglyze XR, a combination of Metformin and saxagliptin, controls blood sugar levels. Metformin decreases glucose (blood sugar) production in the liver and decreases absorption of glucose by the intestines. Saxagliptin regulates insulin levels during digestion.
In 2016, the FDA added a warning about heart failure risks to the labels of Onglyza and Kombiglyze XR alerting healthcare professionals to consider the risks and benefits of the drugs in patients who have known risk factors for heart failure. Additionally, healthcare professionals should counsel patients regarding symptoms of heart failure and observe patients for signs and symptoms of heart failure, including:
- Swollen ankles, feet, legs, or stomach
- Feeling tired, weak, or fatigued
- Shortness of breath
- Difficult breathing when lying down
If you have suffered heart failure after taking Onglyza or Kombiglyze XR, Contact Us for a free medical legal consultation.